An FDA panel is expected to endorse a new blood-thinning drug by Eli Lilly. The decision could have a big impact on how powerful drugs with potentially risky effects are brought to the market. Dan Grech reports.
A group of health care reformers meets today in Washington to address some dormant issues. Lawmakers are encouraged by the attention of President Obama, and some feel reform is imminent. John Dimsdale reports.
COBRA allows former employees to pay to continue their health care coverage after they've left their job. But as Sally Herships reports, the costs of the program can make it difficult for some families to see the benefits.
It's hard to avoid Proctor and Gamble's global presence and scores of beauty products. But some of the company's brands are starting to lose out to cheaper generics. Janet Babin explores the consumers' perspective.
The affluent town of Edina, Minn., has been slowly feeling the effects of layoffs and stretched budgets. Annie Baxter visits the town's biggest employer to see how it's coping with the economic stress.
Pfizer announced a deal this morning to buy Wyeth for more than $68 billion, which it will do with the help of bailed-out banks. What does this say about the lending health of these banks? Steve Henn reports.
Reports out this morning say mega pharmaceutical company Pfizer is in talks to buy competitor Wyeth in a potential $60 billion deal. Pfizer may be considering the move because it's running out of options. Ashley Milne-Tyte reports.